Effective DMTs can normalize NFL levels, such as in treatment of multiple sclerosis and spinal muscular atrophy, by reducing NFL levels, and as such, serve as a therapeutic response biomarker that correlates with clinical efficacy of treatment [260, 261]. The gene discussed is NEFL; the disease is spinal muscular atrophy.